Single Donor Plasmapheresis for COVID-19: An Experience from a Tertiary Care Hospital Based Blood Centre

Introduction: Corona Virus Disease-2019 (COVID-19) caused by Severe Acute Respiratory Syndrome Corona Virus 2 (SARS-CoV-2) became a global health problem since December 2019. No single treatment was found to be effective against COVID-19. Transfusion of COVID Convalescent Plasma (CCP) was found to be a useful and logistically feasible therapeutic strategy in COVID-19. Aim: To study the feasibility of single donor plasmapheresis for COVID-19, to analyse statistical significance of clinico- demographical data and biochemical parameters of convalescent plasmapheresis donors and to further study the adverse reactions and technical problems that occurred during the procedure of single donor plasmapheresis. Materials and Methods: A prospective observational study was carried out over a period of 10 months from June 2020 to March 2021. The study included 235 screened donors and 50 procedures for single donor plasmapheresis (SDPs). Donors were selected as per the standard criteria given by Indian Council of Medical Research (ICMR). All plasmapheresis procedures were performed on an automated blood cell separator. The results were tabulated and statistical analysis was performed using Statistical Package for the Social Sciences (SPSS) software. Results: Out of 235 prospective CCP donors, 164 (69.78%) were found eligible. The causes of non eligibility donors were unwillingness to donate, absence of SARS-CoV-2 antibody, Transfusion Transmitted Disease (TTD) positivity, and improper haematological parameters. Actual plasma donations were carried out in 50 (21.27%) eligible donors. Therapeutically needed amount of CCP (400 mL) could be collected from most of the donors. Adverse reactions were seen in 4 (8%) donors. Conclusion: Adequate amount of CCP could be collected by single donor plasmapheresis with satisfactory technical support. The procedure was well accepted by the prescreened donors with minimum adverse reactions.